No evidence of HIV replication in children on antiretroviral therapy
Gert U. Van Zyl, … , John W. Mellors, Mary F. Kearney
Gert U. Van Zyl, … , John W. Mellors, Mary F. Kearney
Published September 11, 2017
Citation Information: J Clin Invest. 2017;127(10):3827-3834. https://doi.org/10.1172/JCI94582.
View: Text | PDF
Concise Communication AIDS/HIV Virology

No evidence of HIV replication in children on antiretroviral therapy

Abstract

It remains controversial whether current antiretroviral therapy (ART) fully suppresses the cycles of HIV replication and viral evolution in vivo. If replication persists in sanctuary sites such as the lymph nodes, a high priority should be placed on improving ART regimes to target these sites. To investigate the question of ongoing viral replication on current ART regimens, we analyzed HIV populations in longitudinal samples from 10 HIV-1–infected children who initiated ART when viral diversity was low. Eight children started ART at less than ten months of age and showed suppression of plasma viremia for seven to nine years. Two children had uncontrolled viremia for fifteen and thirty months, respectively, before viremia suppression, and served as positive controls for HIV replication and evolution. These latter 2 children showed clear evidence of virus evolution, whereas multiple methods of analysis bore no evidence of virus evolution in any of the 8 children with viremia suppression on ART. Phylogenetic trees simulated with the recently reported evolutionary rate of HIV-1 on ART of 6 × 10–4 substitutions/site/month bore no resemblance to the observed data. Taken together, these data refute the concept that ongoing HIV replication is common with ART and is the major barrier to curing HIV-1 infection.

Authors

Gert U. Van Zyl, Mary Grace Katusiime, Ann Wiegand, William R. McManus, Michael J. Bale, Elias K. Halvas, Brian Luke, Valerie F. Boltz, Jonathan Spindler, Barbara Laughton, Susan Engelbrecht, John M. Coffin, Mark F. Cotton, Wei Shao, John W. Mellors, Mary F. Kearney

×

Figure 1

Properties of HIV-1 infection in the 10 children studied.

Options: View larger image (or click on image) Download as PowerPoint
Properties of HIV-1 infection in the 10 children studied. HIV sequence d...
HIV sequence diversity was measured as the APD at the indicated time points. Divergence was measured using a test for panmixia, with a P value of less than 0.001 considered significant after correcting for multiple comparisons (8), and by measuring the root-to-tip distances of sequences on phylogenetic trees (longer branches over time indicate viral evolution). A 1-sample t test was used to determine if there was a significant change in APD on ART, and a 2-tailed F test was used to determine whether the root-to-tip slopes were significantly different from 0. All branches are shown as the p-distance in the NJ trees. Baseline HIV sequences were either from PBMC DNA (red triangles) or plasma RNA (red circles), and sequences for long-term ART were all from PBMC DNA (black triangles), sampled at the indicated time points. Blue brackets show sequences with evidence of HIV evolution. Plots to the left of the trees show the plasma HIV RNA viral load (VL) as a function of age. Red and black arrows on the plots indicate the time of collection of samples analyzed by SGS. Red vertical arrows indicate the patient’s age at ART initiation. White symbols indicate samples with an undetectable VL, plotted at the limit of sensitivity of the assay used. The apparent decline in the level of undetectable VL in some samples is due to a switch to an assay with a lower limit of detection. (A and B) Patients with detectable viremia for more than 1 year after the time of the first sample. (C–J) Patients with undetectable viremia for all samples taken after the first sample. The blue arrow indicates a sequence that was omitted in 1 sensitivity analysis, as discussed in the text. Results from a total of 20 samples are included in this figure.